CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
02 mai 2024 07h00 HE
|
CytoSorbents
CytoSorbents to Host Virtual KOL and Analyst-Investor Day on May 6, 2024 to review U.S. and Canada STAR-T Pivotal Trial Topline Results
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
17 avr. 2024 07h00 HE
|
CytoSorbents
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
28 déc. 2023 07h00 HE
|
CytoSorbents
CytoSorbents Provides Update on STAR-T Trial and Final Independent DSMB Recommendation
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
13 déc. 2023 09h15 HE
|
CytoSorbents
CytoSorbents Strengthens Balance Sheet with $10.3M Registered Direct Offering. Insiders invest $435,000
CytoSorbents to Present at the 8th Annual Dawson James Conference
05 oct. 2023 07h00 HE
|
CytoSorbents
CytoSorbents to Highlight Company Progress at Dawson James Small Cap Investor Growth Conference
CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial
07 juil. 2023 07h07 HE
|
CytoSorbents
PRINCETON, N.J., July 07, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood...
CytoSorbents Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial Without Modifications Following Second Scheduled Safety Review
15 juin 2023 07h00 HE
|
CytoSorbents
PRINCETON, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents’ Pivotal STAR-T Trial Reaches Second Key Milestone With 80 Patients Enrolled
20 avr. 2023 07h00 HE
|
CytoSorbents
PRINCETON, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...